Lupin rose 1.82% to Rs 726.35 at 14:26 IST on BSE after consolidated net profit surged 162.19% to Rs 408.08 crore on 34.41% increase total income from operation (net) to Rs 2,585.82 crore in Q4 March 2013 over Q4 March 2012.
The result was announced during trading hours today, 8 May 2013.
Meanwhile, the BSE Sensex was up 67.82 points, or 0.34%, to 19,956.77.
On BSE, 2.77 lakh shares were traded in the counter as against an average daily volume of 53,698 shares in the past one quarter.
The stock hit a high of Rs 738.80 so far during the day, which is also a record high for the counter. The stock hit a low of Rs 720.40 so far during the day. The stock had hit a 52-week low of Rs 507 on 15 June 2012.
The stock had outperformed the market over the past one month till 7 May 2013, rising 15.35% compared with the Sensex's 7.80% rise. The scrip had also outperformed the market in past one quarter, rising 20.15% as against Sensex's 1.58% rise.
Also Read
The large-cap company has an equity capital of Rs 89.53 crore. Face value per share is Rs 2.
Lupin's consolidated net profit rose 51.46% to Rs 1314.16 crore on 36.24% increase total income to Rs 9669.15 crore in the year ended March 2013 over the year ended March 2012.
Lupin is a pharmaceutical company producing and developing a wide range of branded and generic formulations and active pharmaceutical ingredients. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB and Cephalosporin segment.
Powered by Capital Market - Live News